ReviewImmunologic research2026
Adapting covid-19 vaccination through targeted approaches: FDA-approved vaccines for the 2025-2026 season.
Review in Immunologic research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the identification of SARS-CoV-2 in late 2019, the continuous evolution of viral variants has represented a challenge to vaccination efforts worldwide. The recent emergence of Omicron viral sublineages has urged the need for updated vaccine formulations in order to maintain efficacy, especially among high-risk populations who are susceptible to severe COVID-19 manifestations. This review aims to comprehend how COVID-19 vaccination strategies evolved and to accentuate FDA-approved vaccines for the 2025–2026 season. The 2025–2026 FDA-approved vaccines- Pfizer-BioNTech’s Comirnaty® LP.8.1, Moderna’s Spikevax LP.8.1 (and mNEXSPIKE), and Novavax’s Nuvaxovid LP.8.1-target the JN.1 variant and elicit strong neutralising antibody responses. Real-world results suggest a relatively low risk of hospitalisation and mortality connected to COVID-19 among persons aged 65 years and older. Safety profiles were consistent with previous formulations, and no new safety concerns were noted. Economic models further add to the cost-effectiveness of vaccination in lowering hospitalisations and healthcare burden in high-risk groups. COVID-19 Vaccinations updated for the 2025–2026 season are highly immunogenic and well protective against severe COVID manifestations in a high-risk cohort. Targeted vaccination strategies, tuned to the variants’ changing dynamics, are required to diminish COVID-19’s global impact while ensuring equity in protection for the most vulnerable population segments.
Indexed as
Identifiers
41831154What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.